About Us
Asia Air WatchLive PM2.5 Medical Alerts
Research Watch
•स्क्रिनमा देखिने चुरोट: सुर्तीजन्य हानि न्यूनीकरण नीतिमा दक्षिण एसियाले अझै के छुटाइरहेको छ•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs•स्क्रिनमा देखिने चुरोट: सुर्तीजन्य हानि न्यूनीकरण नीतिमा दक्षिण एसियाले अझै के छुटाइरहेको छ•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs

Incremental associations of pharmacological components in heart failure with mildly reduced or preserved ejection fraction: a systematic review and component network meta-analysis.

Researchers

Mohammad Ali Omrani, Bala Swetha Baskaran, Atefeh Jafari, Lujain Ez Eddin, Fatemeh Ahmadi, Manik Chhabra, Mê-Linh Lê, Sheikh Abdullah, Kristin Clemens, Flory T Muanda

Abstract

We conducted a component network meta-analysis (CNMA) of phase 3/4 randomized trials to evaluate incremental effects of pharmacological therapies in heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF; LVEF > 40%). MEDLINE, Embase, and Cochrane were searched through 1 August 2025 (updated 30 March 2026). We performed an additive CNMA evaluating cardiovascular death or first heart failure hospitalization (HFH) and assessed certainty of evidence. Twenty-four trials and five secondary reports were included. The primary network was sparse (10 trials, 12 regimens), constraining interaction detection and component stability. Incretin-based interventions (pooling semaglutide and tirzepatide, iHR 0.69, 95% CI 0.53-0.91), SGLT-2 inhibitors (0.80, 0.74-0.88), ARNis (0.82, 0.68-0.99), and MRAs (0.89, 0.81-0.98) showed significant component associations, driven principally by fewer HFHs. No drug class significantly reduced mortality. SGLT-2 inhibitors and MRAs remained significant across sensitivity analyses except LVEF ≥ 50%, with SGLT-2 inhibitors most precise. ARNi benefits lost significance under stricter background therapy thresholds (>60%) and contemporary trial restrictions. Evidence for incretins was low-certainty and sensitive to trial selection. SGLT-2 inhibitors and MRAs provide the most robust incremental benefit, while evidence for other drug classes remains context-dependent. These findings should guide research priorities rather than define combination regimens. http://www.crd.york.ac.uk PROSPEROidentifier is CRD420251107058.
Source: PubMed (PMID: 43065287)View Original on PubMed